Research Article| Volume 56, 103235, November 2021

MRI but not demographic or clinical characteristics differ between familial and sporadic MS cases

Published:September 10, 2021DOI:


      • The frequency of plaques in the periventricular area was significantly higher in sporadic MS patients.
      • The callosal plaques were more common in familial MS patients.
      • No significant differences were observed between demographic and clinical characteristics.



      Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease. The prevalence and incidence of MS in Iran is high and is rising over time. This study was conducted to compare the demographic, clinical features and MRI findings of MS patients with history of the disease in the first-degree family members (fMS) with sporadic MS patients (sMS) to determine the importance of genetic or non-genetic factors in the development of the disease and its effect in diagnostic and therapeutic modalities.


      Among the 185 patients admitted to the study, 62 were fMS patients and 123 were sMS patients. All patients underwent clinical examination and data was gathered on age, sex, age of onset, symptoms, number of attacks, disease course, family history, disease-modifying drugs, and other accompanying diseases as well as MRI findings and EDSS scores.


      In this study, we demonstrated that the frequency of plaques in the periventricular area was significantly higher in sMS patients (97.56% vs 88.71%, p = 0.01) while the callosal plaques were more common in fMS patients (62.9% vs 47.97%, p = 0.05) which was statistically borderline and nonsignificant. In other evaluated parameters, no significant difference was observed.


      In our study, no significant difference was observed between the demographic and clinical characteristics of fMS and sMS patients, while there was a significant difference between the two groups in MRI findings.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Andrijauskis D.
        • Balnyte R.
        • Keturkaite I.
        • Vaitkus A.
        Clinical and diagnostic features of patients with familial multiple sclerosis.
        Med. Hypotheses. 2019; 131109310
        • Azami M.
        • YektaKooshali M.H.
        • Shohani M.
        • Khorshidi A.
        • Mahmudi L.
        Epidemiology of multiple sclerosis in Iran: a systematic review and meta-analysis.
        PLoS ONE. 2019; 14e0214738
        • Curtius F.
        Multiple Sklerose und Erbanlage.
        Thieme, 1933
        • Degenhardt A.
        • Ramagopalan S.V.
        • Scalfari A.
        • Ebers G.C.
        Clinical prognostic factors in multiple sclerosis: a natural history review.
        Nat. Rev. Neurol. 2009; 5: 672-682
        • Eichau S.
        • Spelman T.
        • Izquierdo G.
        • Laffaldano P.
        • Oreja-Guevara C.
        • Butzkueven H.
        • Larochelle C.
        • Boz C.
        • Terzi M.
        • Alroughani R.
        • Ferraro D.
        Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form.
        Mult. Scler. J. 2018 Oct 1; 24 (1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD): 24-25
        • Etemadifar M.
        • Sajjadi S.
        • Nasr Z.
        • Firoozeei T.S.
        • Abtahi S.H.
        • Akbari M.
        • et al.
        Epidemiology of multiple sclerosis in Iran: a systematic review.
        Eur. Neurol. 2013; 70: 356-363
        • Guodmundsson K.R.
        Clinical studies of multiple sclerosis in Iceland.
        Acta Neurol. Scand. 1971; 47: 1-78
        • Harirchian M.H.
        • Fatehi F.
        • Sarraf P.
        • Honarvar N.M.
        • Bitarafan S.
        Worldwide prevalence of familial multiple sclerosis: a systematic review and meta-analysis.
        Mult. Scler. Relat. Disord. 2018; 20: 43-47
        • Hawkins S.A.
        • McDonnell G.V.
        Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.
        J. Neurol. Neurosurg. Psychiatry. 1999; 67: 148-152
        • Huang W.J.
        • Chen W.W.
        • Zhang X.
        Multiple sclerosis: pathology, diagnosis and treatments.
        Exp. Ther. Med. 2017 Jun 1; 13: 3163-3166
        • Jersild C.
        • Svejgaard A.
        • Fog T.
        HL-A antigens and multiple sclerosis.
        Lancet North Am. Ed. 1972; 299: 1240-1241
        • Katsavos S.
        • Artemiadis A.
        • Davaki P.
        • Stamboulis E.
        • Kilindireas K.
        • Anagnostouli M.
        Familial multiple sclerosis in Greece: distinct clinical and imaging characteristics in comparison with the sporadic disease.
        Clin. Neurol. Neurosurg. 2018; 173: 144-149
        • Kremenchutzky M.
        • Rice G.P.A.
        • Baskerville J.
        • Wingerchuk D.M.
        • Ebers G.C.
        The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
        Brain. 2006; 129: 584-594
        • Lublin F.D.
        • Reingold S.C.
        Defining the clinical course of multiple sclerosis: results of an international survey.
        Neurology. 1996; 46: 907-911
        • Millar J.H.
        • Allison R.S.
        Familial incidence of disseminated sclerosis.
        Ulster Med J. 1954; 23 (Suppl): 29
        • Miller D.
        • Barkhof F.
        • Montalban X.
        • Thompson A.
        • Filippi M.
        Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.
        Lancet Neurol. 2005; 4: 281-288
        • Nourbakhsh B.
        • Mowry E.M.
        Multiple sclerosis risk factors and pathogenesis.
        CONTINUUM. 2019; 25: 596-610
        • Phadke J.G.
        Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland.
        J. Neurol. Neurosurg. Psychiatry. 1987; 50: 523-531
        • Pratt R.T.C.
        • Compston N.D.
        • McALPINE D.O.U.G.
        The familial incidence of disseminated sclerosis and its significance.
        Brain. 1951; 74: 191-232
        • Rojas J.I.
        • Patrucco L.
        • MIguez J.
        • Sinay V.
        • Cassara F.P.
        • C+íceres F.
        • et al.
        Disease onset in familial and sporadic multiple sclerosis in Argentina.
        Mult. Scler. Relat. Disord. 2016; 6: 54-56
        • Salehi Z.
        • Almasi-Hashiani A.
        • Sahraian M.A.
        • Eskandarieh S.
        Epidemiology of familial multiple sclerosis: a population-based study in Tehran during 1999–2018.
        Mult. Scler. Relat. Disord. 2020 Aug 1; 43102178
        • Walton C.
        • King R.
        • Rechtman L.
        • Kaye W.
        • Leray E.
        • Marrie R.A.
        • Robertson N.
        • La Rocca N.
        • Uitdehaag B.
        • van der Mei I.
        • Wallin M
        Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS.
        Mult. Scler. J. 2020 Dec; 26: 1816-1821